RxDoctor Payments Data

Victoria Jacobs, APRN

Family · Middleburg, FLNPI 1417562877

Payments from drug & device makers

$3,367in general payments, 2019–2025

Across 140 payments — averaging $24.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$572
  • AbbVie$422
  • Boehringer Ingelheim$308
  • Abbott$282
  • Amgen$228
  • Idorsia Pharmaceuticals US Inc$182
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$3,367100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,367 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$81,368
Medicare patients
485
Services billed
1,017

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban44$44,053
JardianceEmpagliflozin36$43,619
TrulicityDulaglutide34$40,495
OzempicSemaglutide28$36,622
MounjaroTirzepatide30$30,436
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$20,421
JanuviaSitagliptin Phosphate11$9,028
SymbicortBudesonide/Formoterol Fumarate19$6,247
Jentadueto XrLinagliptin/Metformin Hcl11$5,550
PaxlovidNirmatrelvir/Ritonavir26$3,992
Albuterol Sulfate HfaAlbuterol Sulfate112$3,246
Levothyroxine Sodium197$2,078
Omeprazole111$2,070
Gabapentin118$1,951
Atorvastatin Calcium178$1,528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$167$70,93164 claims
Boehringer IngelheimJardiance, Jentadueto Xr$308$49,16947 claims
PfizerEliquis, Paxlovid$70$48,04470 claims
Novo NordiskOzempic$76$36,62228 claims
GSKTrelegy Ellipta$180$20,42125 claims
AstraZenecaSymbicort$572$6,24719 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$20$2,078197 claims
AbbVieSynthroid$422$1,05811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.

Other family in Middleburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →